Rare disease advocacy group urges Trump administration to restore FDA clarity

84% of biotech investors surveyed said they reduced, paused or exited rare-disease investments amid FDA uncertainty; about two-thirds of biotech companies reported harder capital raising over the past 12 months. CBER approved five orphan drugs in 2025 but issued four CRLs and one pre-marketing setback (rejecting ~50% of late-stage programs), and in Q1 2026 approved one orphan drug vs two CRLs (compared with eight approvals and two CRLs at the FDA drug center). Dr. Vinay Prasad is leaving CBER at end-April and a coalition of ~100 advocacy groups, executives and investors has urged the administration to restore regulatory clarity.

Analysis

Capital scarcity in specialized biotech markets cascades into lengthened development timelines and higher probability of dilution for cash-intensive gene and cell therapy developers; absent new funding channels those companies will likely need 12–24 months of runway extensions, which historically translate into 20–40% equity dilution or distressed M&A outcomes for small-cap issuers. Protocol design conservatism (larger sample sizes, more robust endpoints) materially raises near-term cohort sizes and per-trial costs — a 30–50% increase in trial budget is plausible for first-in-class gene therapies, compressing IRR expectations for venture and crossover investors.

The immediate reallocation of risk budgets creates clear second-order winners: providers of high-performance compute and data infrastructure capture flows from allocators exiting idiosyncratic biotech risk (rotation window = 1–6 months), and ad/monetization platforms able to show ROI near-term benefit from cyclical marketing reallocation. Supply-chain nodes that serve iterative biologics (standardized CDMO lines, assay vendors) face short-term volume troughs but remain strategic chokepoints — attractive targets for acquisitive strategics if public valuations gap down 30–60%.

Catalysts to watch with tight time horizons: public signals of regulatory clarity or a revised guidance memo can trigger a sector-wide rerating within 30–90 days; conversely, a sustained hardening of approval standards or prolonged leadership vacuum would push funding freezes into a 12–18 month credit/drain cycle. Tail risks include headline-driven block trades or covenant breaches at mid-cap developers that can cascade into fire-sale valuations absent bridge financings.

Contrarian angle: much of the downside is priced as permanent impairment, but orphan/rare assets carry idiosyncratic scarcity value and high pricing power that shorten payback if approvals resume — a defensive playbook of event-driven M&A exposure (buyouts, asset purchases) will outperform passive short-biotech exposure if regulatory signals flip within the next 3–6 months.

Key Decisions for Investors

• Short uniQure (QURE) via a 9–12 month put spread sized at 1.0–1.5% NAV (buy deep-OTM puts / finance with nearer-term puts) — thesis: heightened probability of additional data requirements and dilution. Target 60–120% payoff if a major negative regulatory event or financing need occurs; hard stop at 30% of premium.
• Long Super Micro Computer (SMCI) with a 6–12 month call spread or 1.0% NAV equity position — thesis: rotation into AI compute and away from biotech risk will persist near term. Target 30–60% upside on continued fund flows; cut to 0.5% NAV or unwind if relative performance vs. tech index underperforms by >10% in 6 weeks.
• Pair trade: short QURE (0.75% NAV) / long SMCI (0.75% NAV) to isolate regulatory risk vs. AI rotation. Aim for neutral beta to broader market; take profits if spread widens by 25–35% or tighten if regulatory clarity reduces QURE downside within 90 days.
• Defensive collars on Moderna (MRNA): buy protective 6–12 month puts sized to cover 50% of equity exposure while selling calls to fund cost — use this to retain upside from commercial franchises while insulating against headline-driven draws. Reduce hedge if regulatory guidance is materially clarified within 60–90 days.
• Opportunistic long AppLovin (APP) 6–9 month call position sized 0.5% NAV to capture ad reallocation tailwinds; exit on 40–60% realized gains or if CPI/consumer demand collapse signals ad spend pullback. Use as a liquidity-efficient way to redeploy proceeds from biotech shorts into growth exposure.